Cibotercept

N/A

Report date: 2026/02/20 20:02:00

Base Information

Drug NameCibotercept
Drug Alias NameKER-012RKER-012
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTransforming growth factor beta inhibitors
TargetsTransforming growth factor beta
Therapy Area/IndicationsHeart Failure, SystolicHeart Failure, DiastolicPulmonary Arterial Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesWorldTaiwan +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesKeros Therapeutics IncKeros Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKeros Therapeutics IncUniversity Of MichiganOakland University
Inactive CompaniesN/A
Active IndicationsHeart Failure, SystolicHeart Failure, DiastolicPulmonary Arterial Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksKEGG